Rayca Precision, founded in late 2021, has a mission to deal with cancer diseases and empower individuals to lead longer and healthier lives. The company aims to achieve this goal by reinventing, designing, and implementing cutting-edge technologies in translational and clinical medicine to systematically treat and monitor cancer.

Utilizing precision oncology, Rayca Precision strives to assist oncologists manage cancer innovatively, providing cancer patients with care tailored to their affliction, biological profile, and characteristics. The company intends to leverage Artificial Intelligence and high-throughput transcriptome and genome profiling to monitor cancer from its earliest stages and develop the most optimal treatment plan to improve patient survival rates.

Aside from cancer-specific analytical solutions for clinical research, Rayca Precision also aims to assist biotech and pharma in transferring therapeutic solutions to clinical trials more effectively.